clinical Ûresearch enterprises a virtuous cycle
TRANSCRIPT
![Page 1: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/1.jpg)
ClinicalÛ ResearchEnterprisesAVirtuousCycle
eMERGE
![Page 2: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/2.jpg)
TheConceptofEvidence
HumGenDiscoveryp-valuesentrenched1(patent)vsalot(e.g.ExAC)
ReplicationPriorexpectation
TranslationClinicalimpressionentrenchedProfessionalstandards(expertsandsocieties)Doesnotlikecontradictorydata
ExperimentalDiscovery“Theperfectexperiment”p-valuesReplicationPriorexpectation
![Page 3: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/3.jpg)
EvaluatingtheClinicalValidityofGene-BasedAssociationsStrande etal.AJHG,2017
![Page 4: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/4.jpg)
ClinicalGenomeResource
Rehm etal.ClinGen.
NEJM2015
www.clinicalgenome.org
![Page 5: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/5.jpg)
ClinGen ScoringSystem(s)
![Page 6: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/6.jpg)
Somecommentsabout“actionability”Hunteretal.(2016)GeneticsinMed:Severity,Effectiveness,NatureofIntervention
Whatistheaction?Usuallyconsideredmodifiedtreatmentorpreventivemeasure
appliedtothepatient.Reportingis,byitself,anaction.Thepatient’sfamily?Family
planning?
Whatistheevidenceaboveandbeyondtraditionalevidence(e.g.riskfactors)?
e.g.CholesterollevelsvsLDLRmutationDowetreatthegenotypeorthephenotype?
Whatistherisk/harmofamisappliedaction?Itisassumedtobehigh,butitmaybequitelowinsomecases
![Page 7: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/7.jpg)
Whatwehaveseensofarisgreat,but…...
![Page 8: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/8.jpg)
….itdoesn’tscale.
![Page 9: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/9.jpg)
NIHSequencingEfforts
TOPMed CCDG
● CVDCohorts
● >130KWGS● Multi-omics
● LSACEvolved● 22KWGSFreeze
● MultipleCohorts
● 15KCustomPanel
● ClinicalSignout● HGSC-cl
● 1KFamilyWGS● 11KCase/ControlWES
![Page 10: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/10.jpg)
Neptune
GenesofInterest
VariantCalling
KnowledgeBase
ManualReview
AutomatedReport
BluePrint
PhenotypesofInterest
Mercury
SampleData
VIPFilter
GeneList
RawVCFs
FinalReport
VIPVariants
KnownPositive
NegativeReport
NegativePre-Report
PositiveReport
NovelPositive
SignoutPortal
ReviewPortal
NovelClinicalSignificance
ClinicalDBs
Neptune:AutomatedClinicalReporting
![Page 11: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/11.jpg)
BAYLOR HGSC STATUS UPDATE: Interpretation & ReportingALL sites, n = 2,417, Variable phenotypes
NonindicationbasedConsensusreturnable
results
NonindicationbasedSite-specificreturnableresults
IndicationbasedReturnableresults
Indications Total Pos. Neg.
Cardiomyopathy 1 1 0
CardiacArrythmia 31 0 31
Hyperlipidemiaa 637 16 621
ColorectalCancer 279 2 277
Breast/OvarianCancerb
72 16 56
OthersincludeMEFV,HNF1A,CACNA1A,OTC,COL3A1,SMAD3,SMAD4(x1),MH(x3)
Positive3.7%
(n=45) aNegative96.5%(n=985)
Positive3.5%(n=35) Negative
97%(n=2,343)
Positive3.0%
(n=74) a
a3patientsnotincludedwithindicationbasedresults
Negative96.3%
(n=1,164)
aHyperlipidemiaincludesFH,hypertriglyceridemia,hyperlipidemiaandcoronaryarterydiseaseindications.b Allreturnedgenesbelongtothe68consensusexceptforCHEK2inabreastcancerpatient
PathandLpathvariantsinNUspecificreturned
Total
CHEK2 24
ATM 7
SERPINA1 2
MC4R 3
KCNE1 6
F11,FLG,KCNE2(x1) 3
n=1,020 n=2,417 n=1,209
a1patienthad2variants
![Page 12: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/12.jpg)
Neptune
KnowledgeBase
ManualReview
AutomatedReport
VIPFilter
FinalReport
VIPVariants
KnownPositive
NegativeReport
NegativePre-Report
PositiveReport
NovelPositive
SignoutPortal
ReviewPortal
NovelClinicalSignificance
ClinicalDBs
Neptune:AutomatedClinicalReporting
![Page 13: Clinical ÛResearch Enterprises A Virtuous Cycle](https://reader035.vdocument.in/reader035/viewer/2022062309/62a6e904524d365aba30aaf3/html5/thumbnails/13.jpg)
Howcanexpertcurationbescaled?